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Abstract
Problem—Maternal tolerance of the fetus is essential for viviparity, yet anti-fetal rejection
occurs in several pregnancy complications. Chronic chorioamnionitis (CCA) is a feature of anti-
fetal cellular rejection. There is a robust association between CCA and maternal seropositivity for
anti-HLA panel reactive antibodies (PRA) at the time of delivery. This longitudinal study was
performed to assess maternal HLA PRA status in early gestation and the temporal evolution of
maternal HLA PRA in the context of CCA and thereby to determine whether HLA PRA during
the course of pregnancy is useful for the detection of anti-fetal rejection.
Method of Study—Maternal sera obtained before 16 weeks of gestation and at delivery were
analyzed for HLA panel reactive antibodies (PRA) in cases with (N=100) and without (N=150)
CCA.
Results—IgG but not IgM HLA class I and II PRA positivity at delivery was higher in cases
with CCA than in those without CCA. IgG HLA class I PRA positivity before 16 weeks of
gestation was higher in cases with CCA than in those without (30.3% vs. 13.3%; p=0.001).
Positive conversion (negative HLA PRA before 16 weeks of gestation but positive at delivery) of
IgG HLA class I and II PRA was significantly associated with CCA. Fetal HLA class I antigen-
specific antibodies were confirmed in 12 of 16 mothers tested who were sensitized to HLA class I
antigens before 16 weeks of gestation.
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Conclusion—Positive maternal HLA PRA before 16 weeks of gestation and the temporal
evolution of maternal HLA PRA are associated with the presence of CCA at the time of delivery.
Maternal IgG HLA PRA has potential to be a monitoring tool of anti-fetal rejection. Furthermore,
the findings herein indicate that subsets of fetuses are exposed to alloimmune HLA antibodies for
months, especially in cases with CCA.
Keywords
chronic chorioamnionitis; human leukocyte antigen; panel reactive antibody; pregnancy; preterm
birth; rejection
Introduction
Maternal tolerance of the fetal semi-allograft is considered essential for viviparity,1–16 and
several investigators have proposed associations between abnormal maternal allogeneic
responses and certain obstetrical syndromes such as recurrent pregnancy loss, fetal growth
restriction, preeclampsia, and spontaneous preterm birth.17–27 However, a specific definition
of maternal anti-fetal rejection in placental pathology has not yet been formulated. Recently,
we proposed that chronic chorioamnionitis (CCA; infiltration of maternal T cells in the
chorioamniotic membranes) represents the placental manifestation of maternal anti-fetal
cellular rejection and that it is the most common lesion found in the placentas of women
delivering after spontaneous preterm labor (with intact or ruptured membranes).28 This
lesion is frequently associated with villitis of unknown etiology, which also represents the
same immunological process in the villous placenta.29–33
Preterm birth is a major health care problem, as there were 13 million preterm births
worldwide in 2005, and its frequency is increasing.34,35 It is the leading cause of perinatal
morbidity and mortality,36 and in the United States, annual costs related to preterm birth are
estimated to be $26 billion.37 Preterm birth is categorized according to two clinical
circumstances: spontaneous and indicated preterm births.36 However, a precise mechanism
of preterm birth still remains elusive in most cases, although infection and/or inflammation,
uteroplacental ischemia, and cervical disorders have been proposed as mechanisms
responsible for preterm birth.38,39 Therefore, there is an urgent need to understand the
mechanisms of disease responsible for spontaneous or indicated preterm births with the hope
of developing primary or secondary prevention.
While histopathological demonstration of leukocyte infiltration is the main diagnostic tool in
patients with clinically suspected ongoing rejection of solid organ transplants such as heart,
liver, and kidney,40–42 the clinical value of chronic chorioamnionitis is quite limited during
the course of pregnancy because it is impossible to take serial biopsies of the placenta or the
chorioamniotic membranes. This presents a major challenge for identification and
monitoring of anti-fetal rejection in pregnant women.
Generation of donor-specific human leukocyte antigen (HLA) antibodies (DSA) is an
important feature of humoral antibody-mediated rejection after allograft transplantation, and
DSA can be used for screening or diagnostic purposes.43–45 HLA sensitization is a risk
factor for poor graft outcome, and HLA panel reactive antibodies (PRA) are commonly used
in clinical practice to assess the HLA sensitization of recipients46,47 and the likelihood of
graft rejection in patients who undergo transplantation.48–51 HLA PRA screenings are being
done before and after organ transplantation, and clinical approaches to reduce the degree of
sensitization such as immunoglobulin administration and plasmapheresis are available.46,47
It also has been shown that de novo HLA antibodies (negative PRA before transplantation
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and positive PRA after transplantation) are associated with a significant decrease in a five-
year graft survival rate for living related kidney transplantation.51
We have recently reported a strong association between chronic chorioamnionitis and
maternal IgG HLA class I PRA positivity.26 Furthermore, the correlation between maternal
and umbilical cord plasma HLA PRA positivity is also robust,26 as maternal IgG antibodies
cross the placenta.52 Therefore, positive maternal HLA PRA, which can be a consequence of
either preformed antibodies before pregnancy or de novo generation during the index
pregnancy, is a marker of maternal sensitization which is required for humoral anti-fetal
rejection.
In this study, we sought to analyze maternal HLA PRA status in early gestation and the
temporal evolution of maternal HLA PRA according to the presence or absence of chronic
chorioamnionitis by undertaking a longitudinal analysis of spontaneous preterm births and
term births.
Materials and Methods
Study population
To determine maternal HLA PRA status in early gestation and the evolution of maternal
HLA PRA during the course of pregnancy according to the presence or absence of chronic
chorioamnionitis subsequently diagnosed at the time of delivery, the pregnant women who
underwent blood sampling before 16 weeks of gestation and at the time of delivery and
whose placentas were available for histopathologic examination were selected from the
Bank of Biological Materials of the Perinatology Research Branch, Eunice Kennedy Shriver
National Institute of Child Health and Human Development, National Institutes of Health,
U. S. Department of Health and Human Services. All patients were Hispanic women who
delivered at the Sótero del Rio Hospital, Santiago, Chile. The study population was divided
according to the presence or absence of chronic chorioamnionitis and gestational age at
delivery: women with chronic chorioamnionitis (N=100: 50 term and 50 spontaneous
preterm deliveries) and women without chronic chorioamnionitis (N=150: 100 term and 50
spontaneous preterm deliveries). Cases of fetal congenital anomalies and multiple gestations
were excluded from this study. Spontaneous preterm deliveries included cases of preterm
labor or preterm prelabor rupture of membranes. Among 250 ‘at the time of delivery’
samples, 242 samples (96.8 %) were obtained within 1 week, 3 samples (1.2 %) within 2
weeks, 3 samples (1.2 %) within 3 weeks, and the remaining 2 samples (0.8 %) within 4
weeks (24 and 25 days) before delivery. Serum samples were kept at −80°C until use. All
patients provided written informed consent. The Institutional Review Boards of the
participating institutions approved the collection and use of biological materials and clinical
data for research purposes.
Placental pathology
Histopathological lesions of the placenta were defined according to diagnostic criteria
proposed by the Perinatal Section of the Society for Pediatric Pathology, which include
lesions consistent with amniotic fluid infection, maternal vascular underperfusion, and fetal
vascular thrombo-occlusive disease.53 Villitis of unknown etiology was diagnosed based on
the histologic criteria previously described,33 and the diagnosis of chronic chorioamnionitis
was made when lymphocytic infiltration into the chorionic trophoblast layer or
chorioamniotic connective tissue occurred as described previously.28 Chronic deciduitis
with plasma cells was defined when lymphoplasmacytic infiltrate was observed in the
decidua basalis.54
Lee et al. Page 3
Am J Reprod Immunol. Author manuscript; available in PMC 2012 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Flow cytometry for HLA panel reactive antibodies
Flow cytometric analyses of HLA class I and class II PRA in maternal sera were performed
using the FlowPRA®-I screening test (One Lambda, Canoga Park, CA, USA) and the
FlowPRA®-II screening test (One Lambda), according to the manufacturer’s instructions.
Class I or class II microbeads were mixed with 20 μl of serum, and incubated for 30 min at
room temperature with gentle rotation. The beads were washed 3 times with 1 ml of
FlowPRA wash buffer by centrifugation at 9,000xg for 2 min, followed by incubation with
100 μl of FITC-conjugated F(ab)2 fragment of Fcγ fragment specific goat anti-human IgG
for 30 min for IgG HLA PRA or with 100 μl of FITC-mouse anti-human IgM at 1:10
dilution for IgM HLA PRA (BD Biosciences, San Jose, CA, USA). After washing the beads
twice with 1 ml of wash buffer and adding 0.5 ml of fixing solution (PBS with 0.5%
formaldehyde), the FL1 fluorescence of 5,000 events was analyzed using BD LSRII flow
cytometry (BD Biosciences). A sample with reactivity of 10% or more was considered
positive for HLA PRA.47,55 For the analysis of IgG isotypes, a biotin-labeled mouse anti-
human IgG1, IgG2, IgG3, or IgG4 antibody (Invitrogen Corp., Carlsbad, CA, USA) was
used instead of FITC-conjugated F(ab)2 fragment of Fcγ fragment specific goat anti-human
IgG in the same kits used above for the second antibody and followed by washing and
incubation with 1μg/ml Streptavidin-APC (eBioscience, San Diego, CA, USA) for another
30 min before flow cytometry analysis.
Fetal HLA genotyping and anti-fetal specificity of maternal HLA antibodies
As maternal-fetal HLA-specific antibodies can be considered analogous to donor-specific
antibodies in organ transplantation settings, we also assessed whether maternal HLA
antibodies were specific for fetal HLA antigens by analyzing fetal HLA genotypes and by
testing maternal sera for fetal HLA-specific antibodies in 16 IgG HLA class I PRA positive
cases before 16 weeks of gestation, whose genomic DNA from fetal cord blood were
available. Fetal HLA specificity of maternal HLA PRA was determined using LABTypeR
SSO typing kits (One Lambda) for fetal HLA genotype and LABScreenR Single Antigen
(One Lambda) for maternal HLA antibody detection with Luminex assay (Luminex
Corporation, Austin, TX, USA), according to the manufacturers’ instructions. Briefly, for
fetal HLA genotyping, locus-specific polymerase chain reaction (PCR) amplification was
performed with 2 μl of genomic DNA from fetal cord blood (20 to 50 ng/μl), D-mix (One
Lambda), locus-specific amplification primers (One Lambda) and Taq polymerase (Applied
Biosystems, Carlsbad, CA, USA). The PCR was conducted in the following cycles: 1 cycle
at 96 °C for 3 min; 5 cycles at 96 °C for 20 s, 60 °C for 20 s, and 72 °C for 20 s; 30 cycles at
96 °C for 10 s, 60 °C for 15 s, and 72 °C for 20 s; 1 cycle at 72 °C for 10 min. Thereafter,
the amplified PCR products were denatured and neutralized, followed by hybridization with
LABType SSO beads at 60°C for 15 min. After 3 washes with wash buffer, the beads were
labeled with R-PE Conjugated Streptavidin and washed twice. Data acquisition was
performed with Luminex 100 (Luminex) and data analysis was conducted with HLA Fusion
2.0 software (One Lambda). For the epitope assessment of maternal HLA antibody, 20 μl of
maternal sera were mixed with 5 μl of Class I or Class II LABScreen beads (One Lambda),
followed by incubation for 30 min at room temperature with gentle shaking. After 3 washes
with wash buffer, the beads were incubated with PE-conjugated anti-human IgG (One
Lambda) for another 30 min at room temperature and washed twice. Thereafter, the samples
were analyzed for data acquisition with Luminex 100 (Luminex). Data analysis was
conducted with HLA Fusion 2.0 software (One Lambda).
Statistical analysis
Medians and ranges for continuous variables and frequencies and percentages for categorical
variables were reported. The Kruskal-Wallis analysis of variance test and the Mann-Whitney
U test or one-way analysis of variance and post-hoc tests were performed to compare
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differences for continuous variables. Proportions were compared using the χ2 test or Fisher’s
exact test for categorical variables. Statistical analyses were performed using the SPSS
version 15.0 (SPSS, Inc., Chicago, IL, USA). All P values were two-sided, and a value of
less than 0.05 was considered statistically significant.
Results
Maternal IgG HLA PRA positivity and chronic chorioamnionitis
Demographic and clinical characteristics of patients in the different study groups are
summarized in Table I. Representative histological features of chronic chorioamnionitis
showing lymphocytic infiltration into the chorionic trophoblast layer or chorioamniotic
connective tissue are shown in Figure 1A and 1B.
At the time of delivery, IgG HLA class I PRA positivity in maternal serum was higher in
patients whose placenta had chronic chorioamnionitis than in those without this lesion
(70.0% vs. 24.0%, P < 0.001) (Figure 2A). In samples obtained before 16 weeks of
gestation, maternal serum IgG HLA class I PRA positivity was also higher in cases with
chronic chorioamnionitis than in those without chronic chorioamnionitis (30.0% vs. 13.3%,
P = 0.001) (Figure 2A). The IgG HLA class II PRA positivity at the time of delivery was
higher in patients with chronic chorioamnionitis than in those without this lesion (36.0% vs.
16.7%, P < 0.001) (Figure 2B). Before 16 weeks of gestation, chronic chorioamnionitis
tended to be associated with a higher rate of positive maternal serum IgG HLA class II PRA,
although the difference did not reach statistical significance (12.0% vs. 6.0%, P = 0.094)
(Figure 2B). Subgroup analyses of patients with term and preterm deliveries showed a
similar difference for the IgG HLA class I and class II PRA positivity in maternal serum at
the time of delivery according to the presence or absence of chronic chorioamnionitis (P <
0.05, for each) However, in the samples obtained before 16 weeks of gestation, a significant
difference in maternal serum IgG HLA class I PRA positivity between the cases with and
without chronic chorioamnionitis was found only in preterm births (34.0% vs. 10.0%, P <
0.01)
We also determined if there is an association between chronic deciduitis with plasma cells
and maternal IgG HLA PRA positivity. Women with chronic deciduitis with plasma cells
had a significantly higher rate of chronic chorioamnionitis than those without (70.5% vs.
33.5%, P < 0.001). As is the case with chronic chorioamnionitis, women with chronic
deciduitis with plasma cells had higher serum IgG HLA class I and class II PRA positivity at
the time of delivery than those without this lesion (HLA class I: 88.6% vs. 30.9%, P <
0.001; HLA class II: 45.5% vs. 19.9%, P < 0.001). Even in samples collected before 16
weeks of gestation, chronic deciduitis with plasma cells was associated with higher positive
rates of maternal IgG HLA class I and class II PRA (HLA class I: 43.2% vs. 15.0%, P <
0.001; HLA class II: 18.2% vs. 6.3%, P = 0.017)
Evolution of HLA PRA seropositivity as a function of gestational age and chronic
chorioamnionitis
To determine the effect of advancing gestational age on the development of IgG HLA PRA
positivity, we compared IgG HLA PRA positivity between samples taken before 16 weeks
of gestation and those obtained at the time of delivery. IgG HLA class I and class II PRA
positivity were significantly higher in the samples obtained at the time of delivery than in
those obtained before 16 weeks of gestation (HLA class I: 42.4% vs. 20.0%, P < 0.001;
HLA class II: 24.4% vs. 8.4%, P < 0.001). Such an evolution of IgG HLA class I and class
II seropositivity as a function of gestational age at blood sampling was observed in all
subgroups stratified according to the presence or absence of chronic chorioamnionitis and
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gestational age at delivery (P < 0.05, for each), except in patients who delivered preterm and
had no chronic chorioamnionitis. Figure 3 shows maternal HLA class I PRA reactivity for
each case. Most patients showed an increase in the reactivity of HLA PRA for samples
obtained at the time of delivery than in those obtained before 16 weeks. This observation
was consistent among the four study groups. Similar results were obtained for HLA class II
PRA (Figure 4).
There were also significant differences in the temporal changes of IgG HLA class I and class
II PRA positivity according to the presence or absence of chronic chorioamnionitis (P <
0.01, for each) (Figure 5). When negative to positive conversion of maternal IgG HLA PRA
(de novo HLA PRA) was defined as negative IgG HLA PRA in a serum sample obtained
before 16 weeks of gestation and positive IgG HLA PRA in the sample obtained at the time
of delivery, a negative to positive conversion of IgG HLA class I PRA was found in 42.0%
of cases with chronic chorioamnionitis, while it was found in 11.3% of cases without
chronic chorioamnionitis (P < 0.001). Negative to positive conversion of IgG HLA class II
PRA was observed in 26.0% of cases with chronic chorioamnionitis, and in 10.7% of cases
without chronic chorioamnionitis (P = 0.001). Only 2% (5/250) of mothers showed negative
conversion for either IgG HLA class I or class II PRA. At the time of delivery, the
proportion of highly sensitized patients (panel-reactivity of 80% or more) was significantly
greater in patients with persistent HLA class I PRA positivity than in those with de novo
positive conversion (46.8% vs. 25.4%, P < 0.05). Similar differences in the temporal
changes of IgG HLA class I and class II PRA positivity according to the presence or absence
of chronic chorioamnionitis were also shown in the subgroups including term and preterm
delivery cases (P < 0.05, for each).
To adjust for the effect of a previous pregnancy as a confounding factor which could have
influence on the HLA PRA positivity, we stratified the study population according to the
presence or absence of a history of previous pregnancy. Both primigravida mothers and
multigravida mothers showed similar differences in the temporal changes of IgG HLA class
I and class II PRA positivity according to the presence or absence of chronic
chorioamnionitis (P < 0.05, for each).
Maternal IgM HLA PRA positivity and chronic chorioamnionitis
As the presence of IgM HLA antibodies and an IgM-to-IgG HLA antibody switch have also
been associated with poor graft outcome in some instances of solid organ transplantation
such as kidney and heart,56,57 we examined whether IgM HLA PRA is generated in the
mother during pregnancy, and whether it is associated with chronic chorioamnionitis. IgM
HLA class I PRA positivity is shown in Figure 6. In samples obtained at the time of
delivery, IgM HLA class I PRA was present in 38.0% and 34.0% of cases with and without
chorioamnionitis, and before 16 weeks of gestation, the frequency was 26.0% and 28.7%,
respectively. Overall, in stark contrast to IgG HLA class I and class II PRA, IgM HLA class
I and class II PRA positivity did not show significant differences according to the
gestational age at maternal blood sampling and with the presence or absence of chronic
chorioamnionitis in both term and preterm births.
Insofar as an IgM-to-IgG HLA antibody switch, among 50 cases positive for IgM but not
IgG HLA class I PRA before 16 weeks of gestation, 19 cases (38%) showed IgG HLA class
I PRA positivity at the time of delivery and 31 cases (62%) did not. Interestingly, cases with
chronic chorioamnionitis had a higher rate of IgM-to-IgG antibody switch (IgG HLA class I
PRA positivity at the time of delivery) than those without chronic chorioamnionitis (71.4%
vs. 25.0%, P < 0.01). Furthermore, among 150 mothers negative for both IgM and IgG HLA
class I PRA before 16 weeks of gestation, 26.7% (n=40) showed IgG HLA class I PRA
positivity at the time of delivery and the cases with chronic chorioamnionitis had higher IgG
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HLA class I PRA positivity at the time of delivery than those without chronic
chorioamnionitis (57.1% vs. 8.5%; P < 0.001)
IgG HLA antibody isotype
In all HLA PRA positive cases, IgG isotypes were further determined by flow cytometry.
The predominant IgG isotypes were IgG1 and IgG3 for both HLA class I and class II PRA.
Among HLA class I PRA positive mothers (n=156), the IgG1 isotype was found in 91.0%,
IgG2 in 18.6%, IgG3 in 18.6%, and IgG4 in 10.9% of the cases. For HLA class II PRA,
IgG1 was found in 70.7%, IgG2 in 1.2%, IgG3 in 18.3%, and IgG4 in 4.9% of the cases.
Fetal HLA specificity of maternal HLA PRA
We further determined whether fetal HLA specific antibodies are detected in HLA PRA
positive mothers. HLA genotyping using genomic DNA identified specific HLA class I and
class II alleles of the fetus as shown in Table II. Overall, 12 of 16 (75.0%) HLA class I PRA
positive mothers had fetal HLA class I specific antibodies. Interestingly, six cases (37.5%)
had fetal HLA class II specific antibodies despite all tested had negative HLA class II PRA
(panel-reactivity < 10%). The frequency that mothers tested had HLA antibodies specific to
each of the fetal HLA class I antigens was 37.5% for HLA-A, 68.8% for HLA-B, and 25.0%
of HLA-C. For HLA class II antigens, 31.3% of cases had antibodies specific against HLA-
DQ, 12.5% against HLA-DR, and 37.5% against HLA class II antigens. When the cases
with chronic chorioamnionitis (N=9) and those without chronic chorioamnionitis (N=7) were
compared, the cases with chronic chorioamnionitis tended to have more chances for
maternal HLA antibodies specific to fetal HLA class I antigens (88.9% vs. 57.1%, P =
0.262) and HLA-A antigen (55.6% vs. 14.3%, P = 0.145).
Discussion
Principal findings
The principal findings of this study show: 1) a significant proportion of mothers have HLA
antibodies early in pregnancy (before 16 weeks of gestation), which can either be preformed
antibodies before conception or antibodies generated de novo. This is particularly the case in
spontaneous preterm births; 2) chronic chorioamnionitis is associated with a significantly
higher maternal IgG HLA PRA positive rate and a seropositive conversion rate during the
course of pregnancy; 3) HLA PRA negative mothers can be highly sensitized (HLA PRA
reactivity > 80%) during pregnancy; 4) maternal IgG HLA PRA is predominantly of the
IgG1 isotype or IgG3 isotype; and 5) maternal HLA antibodies were specific against fetal
HLA antigens (fetus-specific antibody) in 14 of 16 cases tested in this study.
Maternal HLA PRA in early gestation and chronic chorioamnionitis
In the current study, we present evidence that fetal HLA-specific maternal antibodies can be
detected in a subset of women from early pregnancy until the time of delivery. We found
that women whose placentas had chronic chorioamnionitis were more frequently sensitized
to HLA antigens than those without chronic chorioamnionitis. Importantly, such
sensitization was observed more frequently even before 16 weeks of gestation in chronic
chorioamnionitis cases. Of note, although an IgM-to-IgG HLA antibody switch was not
detected in all mothers who had positive IgM HLA PRA before 16 weeks of gestation,
mothers who had an IgM-to-IgG antibody switch were more likely to have chronic
chorioamnionitis. Such data suggest that IgG HLA PRA status in early gestation (a part of
anti-fetal humoral rejection) has promise for predicting subsequent development of chronic
chorioamnionitis. Another implication of our findings is that the immunological process of
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rejection may be of considerable duration in nature as the antibodies can be detected months
before delivery and the diagnosis of chronic chorioamnionitis.
Chronic chorioamnionitis, a feature of maternal anti-fetal rejection
Chronic chorioamnionitis, by definition, is characterized by predominantly lymphocytic
infiltration regardless of etiological agent, and there are examples associated with infection
such as rubella58 and toxoplasmosis.59 However, Gersell et al could not find any evidence of
infection in all of the 17 cases they have reported even by meticulous examinations
including immunohistochemical, bacteriological, and serological studies,60,61 and Jacques
and Qureshi suggested an immunologic nature of chronic chorioamnionitis.62 Its close
association with villitis of unknown etiology28 having features of maternal anti-fetal
rejection29–33 and with humoral antibody-mediated rejection (anti-HLA antibodies and C4d
deposition)26 is also consistent with the concept of anti-fetal rejection. The current study
further supports this concept by demonstrating an association between chronic
chorioamnionitis and maternal serum HLA PRA positivity in early gestation and its
evolutionary patterns during the course of pregnancy.
Nosological considerations of chronic placental inflammation
It seems evident that the vast majority of cases with chronic chorioamnionitis, villitis of
unknown etiology, and chronic deciduitis are placental manifestations of anti-fetal rejection.
Therefore, there is a nosological problem with the current terminology for these lesions as
allograft rejection in the liver or renal transplants is not defined as ‘hepatitis’ or ‘nephritis’,
and refined schema and grading systems of allograft rejection pertinent to each organ have
been developed.63,64 Accordingly, we propose that chronic chorioamnionitis, villitis of
unknown etiology, and chronic deciduitis of an alloimmune nature need to be diagnosed as
anti-fetal rejection of the chorioamniotic membranes, placental disc, and the decidua basalis,
respectively. The terms ‘chronic chorioamnionitis’, ‘chronic villitis’, and ‘chronic
deciduitis’ should be reserved for those cases in which certain associations with other
etiological agents such as virus and other microbial organisms have been documented. The
term ‘villitis of unknown etiology’ also needs to be abandoned. This approach embracing
the pathogenesis of placental inflammatory lesions would minimize problems in the
communications between the clinicians and the scientists and, more importantly, between
the obstetricians and the patients, which would have quite different effects upon the clinical
management of the patients.
While there are differences in the clinicopathological characteristics between chronic
placental inflammation of an alloimmune nature and infectious etiology,31 Benirschke et al
have emphasized the importance of clinical suspicion and meticulous work-up in
differentiating those two different categories of lesions.65 To address this issue, clinicians
and reproductive immunologists would need to work together to develop common
guidelines and the criteria for the diagnosis of anti-fetal rejection in the placenta. In
particular, the extent of basic and clinically relevant work-ups to rule out possibilities of
chronic inflammation of non-alloimmune or infectious etiologies should be clearly defined.
Mechanisms of maternal HLA sensitization during pregnancy
Pregnancy66 is one of the three major risk factors for HLA sensitization along with organ
transplantation67,68 and blood transfusion.69 The prevalence of maternal HLA antibodies
increases as a function of advancing gestation70 and the number of previous pregnancies.71
The placenta has been considered an immuno-privileged organ because trophoblasts do not
express classical HLA class I molecules, except HLA-C.72–74 Instead, they express non-
classical, less polymorphic HLA-E, -F, and –G,75,76 and this accounts, at least in part, for
tolerance at the maternal-fetal interface.
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If HLA PRA is generated as a result of maternal immune response against fetal trophoblast
antigens at the feto-maternal interface, HLA PRA should be largely against HLA-C, which
has been reported to be associated with the development of adverse pregnancy outcomes
such as preeclampsia, fetal growth restriction, and miscarriage through the interaction with
maternal leukocytes (natural killer cells and T cells) in the decidua.25,77,78 However,
maternal fetal HLA-specific antibodies against non-trophoblastic fetal HLA antigens (HLA-
A, -B, and –DR) were found more commonly in the present study, which clearly indicates
that maternal antibody generation in response to fetal HLA antigens is not merely against
trophoblasts which express HLA-C and -G but against different cells expressing classical
HLA antigens.
Potential routes of maternal exposure to non-trophoblastic fetal cells include feto-maternal
hemorrhage79 or retained fragments of placental tissue which may contain non-trophoblastic
cells after delivery.80 However, feto-maternal hemorrhage would be a more plausible
explanation in the cases showing de novo positive HLA PRA conversion across gestation in
the current study. Cohen and Zuelzer have shown that transplacental passage of fetal
erythrocytes increases as a function of gestational age as it was detected in 50% of pregnant
women at the time of delivery.81 In addition, disruption to the integrity of the placental
chorionic villous surface is considered a regular event during pregnancy due to the dynamic
nature of placental circulation.82 It is also known that even during normal pregnancy there is
a variable degree of granulocyte traffic from the fetus to the mother.83 This fetal cell
trafficking,84–86 as well as the presence of cell-free fetal nucleic acids in maternal
circulation,87 have been well-documented. Therefore, variable degrees of continuous or
intermittent influx of non-trophoblastic HLA class I or class II positive fetal cells into the
maternal circulation is easily expected during pregnancy.
Anti-fetal HLA antibodies and the fetus
Intrauterine infection and/or inflammation causes spontaneous preterm parturition, which is
associated with the fetal inflammatory response syndrome and neonatal morbidity.88–90 The
presence of fetal HLA specific antibodies in the majority of the cases tested (75.0%) using
maternal sera obtained before 16 weeks of gestation in this study indicates that there is
chronic fetal exposure to these antibodies, the implications of which are yet to be
determined. In mice, IgG antibodies cross the placenta and localize in several fetal tissues;
their highest levels are found in the blood, thymus, and liver.91 Interestingly, antibodies
persist for a longer period in the fetus than in the placenta. In humans, neonatal alloimmune
neutropenia (NAIN) and neonatal alloimmune thrombocytopenia (NAIT) are well-known
examples of alloimmune reactions, typically presenting against paternal/fetal antigens such
as human neutrophil antigens92,93 and human platelet antigens.94,95 Interestingly, cases of
NAIN and NAIT associated with maternal HLA class I antibodies have also been well-
documented, indicating that HLA sensitization of the mother is a mechanism of disease in
the fetus.96–99
Strengths and Weaknesses
This is the first longitudinal study of maternal HLA PRA status in the context of chronic
chorioamnionitis (anti-fetal cellular rejection) during the course of pregnancy. Fetal HLA
specificity of maternal HLA antibodies was also tested. There are, however, limitations to
this study. We could not determine HLA PRA positivity of patients before pregnancy, as
blood samples were not available for analysis. Therefore, it is possible that panel-reactive
antibodies detected in some pregnant women represent sensitization before the current
pregnancy. Another limitation is that eight samples (3.2 %) among the ‘at the time of
delivery’ samples were obtained between 2–4 weeks before delivery, and it could be argued
that they might not reflect an in vivo situation around delivery. When we analyzed the data
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of the eight samples, five cases represented preterm birth with chronic chorioamnionitis, and
they were negative for both HLA class I and class II PRA. Therefore, it is possible that a
positive conversion occurred late in gestation in some cases, and it is unlikely that the results
of our analyses would have been significantly affected.
Conclusion
Collectively, our study confirms an association between chronic chorioamnionitis and
maternal HLA PRA positivity across gestation. Since maternal anti-fetal rejection in some
cases is persistent, HLA PRA deserves further testing as a monitoring tool for fetal well-
being. Such an approach has potential to assist in exploring antibody-mediated rejection as a
mechanism of disease in the “great obstetrical syndromes”, notably “preterm birth”.
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Figure 1.
Histological features of chronic chorioamnionitis. Maternal lymphocytic infiltration into the
fetal compartments (chorionic trophoblast layer or chorioamniotic connective tissue layer) is
a hallmark of chronic chorioamnionitis. A, A case of preterm labor shows infiltration of
lymphocytes in clusters (arrows) into the chorionic trophoblast layer [Hematoxylin & Eosin
(H&E), X200]. B, Another case of preterm labor in which lymphocytic infiltration (arrows)
involves the chorioamniotic connective tissue layer (H&E, X200).
Lee et al. Page 16
Am J Reprod Immunol. Author manuscript; available in PMC 2012 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
IgG HLA class I and class II PRA positivity according to the presence or absence of chronic
chorioamnionitis. A, Cases with chronic chorioamnionitis had higher rates of IgG HLA class
I PRA positivity than those without chronic chorioamnionitis both before 16 weeks of
gestation and at the time of delivery (P < 0.01, for each). B, Cases with chronic
chorioamnionitis had a higher rate of IgG HLA class II PRA positivity than those without
chronic chorioamnionitis at the time of delivery (P < 0.01), but the difference was not
significant before 16 weeks of gestation.
HLA, human leukocyte antigen; PRA, panel reactive antibodies; CCA, chronic
chorioamnionitis
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Figure 3.
Temporal changes in HLA class I PRA reactivity in study groups stratified according to the
presence or absence of chronic chorioamnionitis and gestational age at birth. A majority of
cases had a tendency toward increase in the panel-reactivity of HLA class I PRA as a
function of advancing gestational age in all study groups. Dashed lines represent the cut-off
value (10%) of panel-reactivity for positive HLA PRA.
HLA, human leukocyte antigen; PRA, panel reactive antibodies; CCA, chronic
chorioamnionitis
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Figure 4.
Temporal changes in HLA PRA class II reactivity in study groups stratified according to the
presence or absence of chronic chorioamnionitis and gestational age at birth. A majority of
cases had a tendency toward increase in the panel-reactivity of HLA class II PRA as a
function of advancing gestational age in all study groups. Dashed lines represent the cut-off
value (10%) of panel-reactivity for positive HLA PRA.
HLA, human leukocyte antigen; PRA, panel reactive antibodies; CCA, chronic
chorioamnionitis
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Figure 5.
Differences in the temporal changes of HLA PRA positivity according to the presence or
absence of chronic chorioamnionitis. A, There were differences in the pattern of temporal
changes in HLA class I PRA positivity according to the presence or absence of chronic
chorioamnionitis (P < 0.001). B, Similar differences in the temporal changes of HLA class II
PRA positivity were observed between the two groups (P = 0.001).
HLA, human leukocyte antigen; PRA, panel reactive antibodies; CCA, chronic
chorioamnionitis
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Figure 6.
IgM HLA class I and class II PRA positivity according to presence or absence of chronic
chorioamnionitis. There were no differences in the rates of IgM HLA PRA positivity
according to the presence or absence of chronic chorioamnionitis– A, HLA class I PRA, and
B, HLA class II PRA.
HLA, human leukocyte antigen; PRA, panel reactive antibodies; CCA, chronic
chorioamnionitis
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